The last puff for this tobacco stock?

Following the announcement of job cuts and the subsequent fall in the share price, is it worth buying stock in British American Tobacco plc (LON: BATS)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There was a time when tobacco companies seemed like the perfect stock to own. They made a frequent purchase item with incredible margins and customer loyalty like no other product.

All of this is in the past. Now tobacco stocks are running out of puff, as people head towards alternative nicotine-based products or give up altogether. Add to that professional investors and wealth managers sometimes avoiding the stocks on ethical grounds, and increasing regulation being faced by the manufacturers of cigarettes (such as US menthol regulation that is a concern among investors). Marketing and usage of cigarettes and related products has been curtailed by governments around the globe in recent years, with devastating effects for businesses operating in the tobacco industry.

Over the past year, the share price of British American Tobacco (LSE: BATS) is down by 16%, reflecting investor sentiment in the industry. Added to the company’s woes is the mountain of debt mostly accumulated from the acquisition of American business Reynolds.

Cloudy outlook

Last week, British American Tobacco announced plans to cut 2,300 jobs by 2020 in readiness for a shift towards non-tobacco products.

The company is in a difficult position. Clearly it needs to move with the times and diversify away from tobacco. Yet the bulk of its £24.5bn revenue comes from traditional cigarettes. And are non-traditional products really the answer to this? Regulation is increasing globally regarding products such as heat-not-burn tobacco and electronic cigarettes.

The safety of some of these products has been questioned too. Reports of six deaths in the US linked to vaping and up to 450 cases of lung problems have spooked some consumers. The Centre for Disease Control has advised people to stop vaping during its investigation and Donald Trump said he is considering a ban on flavoured e-cigarettes.

Yet British American Tobacco obviously thinks the market is shifting towards these products. If it is right, with its brand awareness and infrastructure, it would be in a great position to capitalise on this. However, I have some doubts that the market will grow as fast or as big as it anticipates. I think that a large proportion of usage is as an aid to quit smoking, so customers will only be retained for the short term. This will be more apparent if a flavour ban does come into force in the US or other markets.

From the ashes

Not all of the news is bleak for British American Tobacco. Revenue and profit has been increasing year-on-year, despite falling tobacco volumes. The drop in its share price also makes its price-to-earnings ratio an attractive 11. The prospective dividend is a chunky 6.5% and it could potentially be a great buy for value and growth investors.

The company also has a strong presence in emerging markets, such as Latin America and Asia, as well as a dominant position in the US. I believe this could put it in a great position when it comes to Brexit.

However, with the increased regulation and what could be a declining market, there is too much uncertainty in the industry for me at this time to buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

T Sligo has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »